Lightnews — Scholar-powered news

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 7d

🏷️ for Interest
@rheumnow.bsky.social
@jeffsparks.bsky.social
@pulmpeeps.bsky.social
@icuonepager.bsky.social
@drpujamehta1.bsky.social
@pulmtoilet.bsky.social
@pulmcrit.bsky.social
@thanhneville.medsky.social
@critconcepts.bsky.social
@gretchemaben.bsky.social
@laxswamy.bsky.social

1

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 7d

🆕 Collaboration with RheumNow 🔵
*3-Part Series on Interstitial Lung Disease*

Part 3️⃣: Treatment of #ILD
💊 Medication Options for Rx of ILD
🫁 How to Treat Different ILD Subtypes
🚶🏻‍♀️Holistic Approach to Management ❌🚬

#RheumSky #PulmSky #IPF #Rheum #InterstitialLungDisease

1 1 3

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 16d

Thank you! 😊

1

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 22d

🏷️ for Interest
@jeffsparks.bsky.social
@pulmpeeps.bsky.social
@icuonepager.bsky.social
@nickmark.bsky.social
@drpujamehta1.bsky.social
@rheumcat.bsky.social
@didemsayginmd.bsky.social
@kristenyoung.bsky.social
@pulmtoilet.bsky.social
@pulmcrit.bsky.social

1 2

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 22d

🆕 Collaboration with RheumNow 🔵
3-Part Series on Interstitial Lung Disease

Part 2: Diagnosis & Subtypes of #ILD
👩🏻‍⚕️ What to look for on Physical Exam
🧪 Serologic Testing & Diagnostic Workup
🫁 Differentiating ILD Subtypes on Imaging

#RheumSky #PulmSky #MedSky #InterstitialLungDisease

1 1 6

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Aug 6

🆕 Behçet's Disease: Let’s explore this multi-system #vasculitis 💫

👄 Oral and Genital Ulcers
🩸 DVT, Arterial Aneurysm
👁️ Uveitis
🧠 Neurologic Involvement
🖐️ Cutaneous Disease / Pathergy

#RheumSky #Behcets #Rheumatology

Infographic showing different organ systems affected by Behcets: oral/genital ulcers, skin, vascular, GI, neurologic, ocular and more.

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Aug 6

So often for FUO consults with ID and Heme/Onc 😂

2

Mithu Maheswaranathan, MD @mithurheum.bsky.social · May 8

🆕 2024 ACR Guidelines for Screening, Treatment and Management of Lupus Nephritis 🫘
• Just Released: May 7, 2025 🔥

🔸 New Recommendations for Triple Therapy for Class III/IV + V Lupus Nephritis 🦋
🔸 Reduced ⇣ Dose of PO Steroids after IV Pulse! 💊

#LupusNephritis #RheumSky #NephSky #Lupus

2 7

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Mar 29

Oh sounds interesting! Look forward to reading that.

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Mar 27

🆕 PJP Prophylaxis in #Rheumatology 🫁

🔹Discuss risk factors for PJP infection
🔹Risk Stratify: CD4 count <200 or ALC <500 = ⇡Risk
🔹Review Treatment options and when to stop PPx?

#MedSky #RheumSky #PulmSky #PJP

1 4

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Mar 19

💫 Check out the new Rheum Madness x Rheum One Pagers bracket infographic! 🎉🏀📟

📖 Read most pivotal, innovative studies in #rheum in past 2 yrs
🎙️ Listen to the Rheum Madness podcasts
🏀 Submit Brackets before April 1

@rheummadness.bsky.social
@davidleverenz.bsky.social
@larneson.bsky.social

6 9

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Feb 12

@lupuschat.bsky.social @lupusdnadoc.bsky.social @ashira-md.bsky.social @alhkim.bsky.social @rheumcat.bsky.social @kristenyoung.bsky.social @creakyjoints.bsky.social @lupusresearch.bsky.social

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Feb 12

🆕 #Obinutuzumab (Obi) in Lupus Nephritis: the REGENCY Trial

Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes

#LupusNephritis #RheumSky #NephSky #MedSky #Lupus

1 16 26

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Dec 18

Yes good Q whether earlier targeting in the B-cell pathway with inebilizumab will make a significant difference with broader B cell depletion!

Wonder if anyone else on #RheumSky has thoughts!

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Dec 16

🆕 Visual Abstract with Healio Rheumatology 🟢

🔥 New Therapy for IgG4-Related Disease: INEBILIZUMAB

💉 RCT of inebilizumab (anti-CD19) vs placebo
👥 Adult pts with IgG4-RD involving ≥ 2 organs
📊 Results:⇣flare rate,⇡remission

#IgG4RD #RareDiseases #Rheumatology #Inebilizumab

1 6

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Dec 11

Love this #HealthLiteracy 🙌🏽

1

Reposted by Mithu Maheswaranathan, MD

Sonali J. Bracken, MD, PhD @sjbracken.bsky.social · Dec 8

Happy holidays from the Duke Rheum crew ❄️ ⛄️ 🎄 @mithurheum.bsky.social

1 1 7

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Dec 9

Had so much fun! Thanks for hosting us #DukeRheum #Rheumatology ❄️🎄🎁

1

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Dec 4

Without action, the ongoing #rheumatology physician shortage will only get worse…

@thedaoindex.bsky.social @rheumcat.bsky.social @kristenyoung.bsky.social @vksandhumd.bsky.social

1 6

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Dec 4

Excited to have the opportunity to present on Physician #Burnout in Rheumatology at our division Grand Rounds today.

Thankful many advocates have been voices on this important topic in our current healthcare climate & trend of physicians exiting clinical medicine!

2 2 14

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Nov 27

That’s wild! The journal should help the authors make one if desired

1

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Nov 18

🆕 #ACR24 | Updated Guidelines for Lupus Nephritis Treatment & Management 🫘

Highlights 🔶
• Critical role of renal biopsy
• Differences for treatment by LN Class
• Adjunctive Rx w/ HCQ & RAASi
• GC pulse ⇢ *moderate/low* dose PDN

#Lupus #NephSky #RheumSky #Rheumatology #MedSky

25 58

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Nov 18

Yes! It’s an abbreviation for placebo.

1

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Nov 18

#ACR24 Lupus Nephritis CARE
• By Dr. Maria Dall'Era (UCSF)

Review of #LupusNephritis 🫘
▪️Rx TRIPLE therapy
▪️belimumab vs voclosporin
▪️low level proteinuria (even *UPCR <0.5*) can STILL be associated with disease activity (Class III/IV/V)

#Lupus #RheumSky #NephSky

1 12 31

Mithu Maheswaranathan, MD @mithurheum.bsky.social · Nov 17

🆕 The Great Debate at #ACR24: Is Mixed Connective Tissue Disease (MCTD) a distinct disease entity?

🗳️ Final Vote (n=430 votes)
• 51% = MCTD *is* a unique disease
• 49% = MCTD is not a unique disease

#MixedConnectiveTissueDisease #Rheumatology #RheumSky #MCTD

2 4 18